Table 5.
Diffuse large B‐Cell lymphoma (DLBCL) HRs by time‐dependent statin use
| Age adjusted | Multivariable adjusted | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| DLBCL cases | Hazard ratio | Lower CL | Upper CL | P‐value | Hazard ratio | Lower CL | Upper CL | P‐value | |
| Statin use | |||||||||
| No | 215 | 1.00 | 0.02 | 1.00 | 0.02 | ||||
| Yes | 13 | 0.65 | 0.45 | 0.94 | 0.62 | 0.42 | 0.91 | ||
| Statin type | |||||||||
| No statin use | 215 | 1.00 | 1.00 | ||||||
| Atorvastatin | 1 | 0.69 | 0.40 | 1.19 | 0.18 | 0.69 | 0.39 | 1.23 | 0.21 |
| Fluvastatin | 1 | 0.26 | 0.04 | 1.89 | 0.18 | 0.000 | 0.000 | 0.97 | |
| Lovastatin | 2 | 0.59 | 0.19 | 1.83 | 0.36 | 0.63 | 0.20 | 1.98 | 0.43 |
| Pravastatin | 5 | 0.68 | 0.28 | 1.65 | 0.40 | 0.58 | 0.22 | 1.58 | 0.29 |
| Simvastatin | 4 | 0.83 | 0.45 | 1.52 | 0.54 | 0.81 | 0.43 | 1.54 | 0.53 |
| Lipophilicity | |||||||||
| No statin use | 215 | 1.00 | 1.00 | ||||||
| Lipophilic | 8 | 0.65 | 0.43 | 0.97 | 0.04 | 0.62 | 0.40 | 0.96 | 0.03 |
| Hydrophilic | 5 | 0.79 | 0.37 | 1.67 | 0.53 | 0.72 | 0.32 | 1.63 | 0.43 |
| Statin potency | |||||||||
| No statin use | 215 | 1.00 | 1.00 | ||||||
| Low (Lovastatin, Fluvastatin) | 3 | 0.44 | 0.16 | 1.18 | 0.10 | 0.35 | 0.11 | 1.10 | 0.07 |
| Medium (Pravastatin) | 5 | 0.67 | 0.27 | 1.62 | 0.37 | 0.57 | 0.21 | 1.54 | 0.27 |
| High (Simvastatin, Atorvastatin) | 5 | 0.74 | 0.48 | 1.12 | 0.15 | 0.73 | 0.47 | 1.14 | 0.16 |
Stratified by trial, WHI extension study, and age group.
Base model was adjusted by age.
Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.